Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H974
UPID:
QTRT2_HUMAN
Alternative names:
Queuine tRNA-ribosyltransferase domain-containing protein 1
Alternative UPACC:
Q9H974; A6NGE9; B7Z472; B7Z5R2; J3KR78; Q6IA59
Background:
Queuine tRNA-ribosyltransferase accessory subunit 2, also known as Queuine tRNA-ribosyltransferase domain-containing protein 1, plays a pivotal role in the modification of tRNA. This protein is a non-catalytic subunit of the TGT complex, essential for the base-exchange of guanine with queuine at the anticodon wobble position in tRNAs. This modification results in the formation of the hypermodified nucleoside queuosine, crucial for the proper function of tRNA-Asp, -Asn, -His, and -Tyr.
Therapeutic significance:
Understanding the role of Queuine tRNA-ribosyltransferase accessory subunit 2 could open doors to potential therapeutic strategies.